Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Down 0.9% – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares traded down 0.9% during mid-day trading on Monday. The company traded as low as GBX 540 and last traded at GBX 565. 1,286 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 23,341 shares. The stock had previously closed at GBX 570.

Hemogenyx Pharmaceuticals Trading Down 4.6%

The firm has a market cap of £42.76 million, a price-to-earnings ratio of -4.74 and a beta of 1.49. The company has a 50-day moving average price of GBX 584.44 and a 200 day moving average price of GBX 753.04. The company has a quick ratio of 6.72, a current ratio of 4.04 and a debt-to-equity ratio of 42.86.

Hemogenyx Pharmaceuticals (LON:HEMO) last issued its quarterly earnings results on Monday, September 28th. The company reported GBX (101.70) earnings per share for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.